Julia DiBello
YOU?
Author Swipe
View article: Symptomatic Alzheimer’s Disease Therapy Utilization in 3 National Cohorts
Symptomatic Alzheimer’s Disease Therapy Utilization in 3 National Cohorts Open
Background Although the positive results of the first disease modifying therapies is anticipated to moderately slow disease progression, significant need remains for cognitive enhancers to address AD symptoms and improve quality of life. D…
View article: Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD) Open
Background Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic t…
View article: USE OF RWD TO GENERATE RWE IN THE ALZHEIMER'S DISEASE SETTING: CHALLENGES AND FUTURE DIRECTIONS
USE OF RWD TO GENERATE RWE IN THE ALZHEIMER'S DISEASE SETTING: CHALLENGES AND FUTURE DIRECTIONS Open
There is considerable interest by many stakeholder groups in developing new therapies in Alzheimer’s disease (AD). Increasing interest in the treatment of pre-clinical disease and measurement of associated long term outcomes using RWD is b…
View article: Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism Open
Context Adolescent males with hypogonadotropic hypogonadism (HH) have traditionally been treated with exogenous testosterone (T) or human chorionic gonadotropin (hCG) to produce virilization; however, those modalities do not result in grow…
View article: Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study
Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study Open
Objective To assess and compare the risk of unintended pregnancy in NOMAC-E2 users with levonorgestrel-containing COC (COCLNG) users in clinical practice.Study design In this observational study, new users1 of NOMAC-E2 and COCLNG were recr…
View article: Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism
Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism Open
Objective To assess and compare the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in NOMAC-E2 users with levonorgestrel-containing combined oral contraceptive (COCLNG) users.Study design This large, prospective, o…
View article: Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism
Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism Open
To assess and compare the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in NOMAC-E2 users with levonorgestrel-containing combined oral contraceptive (COCLNG) users. This large, prospective, observational active su…
View article: MP04-02 5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA
MP04-02 5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA Open
You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2016MP04-02 5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA Lauren Wallner, Juli…
View article: Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross‐sectional, <scp>UK</scp> epidemiological study
Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross‐sectional, <span>UK</span> epidemiological study Open
Objectives To compare the prevalence of metabolic syndrome and the components of metabolic syndrome in men aged ≥50 years with and without clinical benign prostatic hyperplasia ( BPH ). Subjects and Methods This was a cross‐sectional study…
View article: Association between low muscle mass, functional limitations and hospitalisation in heart failure: NHANES 1999–2004
Association between low muscle mass, functional limitations and hospitalisation in heart failure: NHANES 1999–2004 Open
This hypothesis-generating study found a synergistic interaction between HF and LMM; the presence of LMM increased the negative effects of HF. HF patients may experience increased disease burden due to LMM.